Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | CHIEF OPERATING OFFICER | January 02, 2026 | January 07, 2026 |
| FEMASYS INCFEMY · Entity 7510 | Director | June 24, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 136,717 |
Ending reported balance
After 2026-01-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-02 · Grant · Acquired 50,000 · Balance 143,377 F1: Represents a restricted share unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2: Each RSU represents a contingent right to receive one ordinary share. Row 2 · 2026-01-02 · Sale · Disposed 3,244 · Balance 140,133 F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Row 3 · 2026-01-05 · Sale · Disposed 3,416 · Balance 136,717 F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.70 inclusive. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2036-01-02 | Direct | 100,000 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Grant · Acquired 100,000 · Balance 100,000 F6: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
F2: Each RSU represents a contingent right to receive one ordinary share.
F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5).
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.70 inclusive.
F6: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares in 36 equal monthly installments thereafter.
FEMASYS INC
Report date June 24, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.67 · Expires 2036-06-24 | Direct | 880 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 880 · Balance 880 F1: The shares underlying the stock option vest one year from the date of grant, assuming continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest one year from the date of grant, assuming continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Aug 12, 2026 01:02 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 880 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001140361-26-032345 · form4.xml · derivative · entry 1 Milnes Alistair · CIK 0001901321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 880 Underlying: Common Stock · 880 shares Expires 2036-06-24 F1 · derivative.exercise_date: The shares underlying the stock option vest one year from the date of grant, assuming continued service. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 3,416 | $6.46 | $22,067.36 |
DisclosureSEC source: 0001901321-26-000002 · form4-01062026_080121.xml · nonDerivative · entry 3 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,717 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.70 inclusive. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001901321-26-000002 · form4-01062026_080121.xml · derivative · entry 4 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2036-01-02 F6 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 3,244 | $6.80 | $22,059.20 |
DisclosureSEC source: 0001901321-26-000002 · form4-01062026_080121.xml · nonDerivative · entry 2 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,133 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001901321-26-000002 · form4-01062026_080121.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,377 F1 · shares: Represents a restricted share unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 03, 2025 Filed Oct 6, 2025 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 978 | $8.41 | $8,224.98 |
DisclosureSEC source: 0001901321-25-000003 · form4-10062025_041008.xml · nonDerivative · entry 2 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,377 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.40 to $8.50 inclusive. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,147 | $8.40 | $9,634.80 |
DisclosureSEC source: 0001901321-25-000003 · form4-10062025_041008.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,355 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.31 to $8.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 21:20 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 966 | $7.44 | $7,187.04 |
DisclosureSEC source: 0001415889-25-019426 · form4-07072025_050706.xml · nonDerivative · entry 2 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,502 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.405 to $7.44 inclusive. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 21:20 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,149 | $7.09 | $8,146.41 |
DisclosureSEC source: 0001415889-25-019426 · form4-07072025_050706.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,468 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.09 to $7.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 21:25 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 17,600 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001140361-25-024008 · form4.xml · derivative · entry 1 Milnes Alistair · CIK 0001901321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2035-06-25 F1 · derivative.exercise_date: The shares underlying the stock option vest one year from the date of grant, assuming continued service. Read SEC document |
| April 03, 2025 Filed Apr 4, 2025 21:35 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,038 | $7.48 | $7,764.24 |
DisclosureSEC source: 0001415889-25-010242 · form4-04042025_050405.xml · nonDerivative · entry 2 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,617 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.43 to $7.50 inclusive. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 21:35 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,133 | $8.02 | $9,086.66 |
DisclosureSEC source: 0001415889-25-010242 · form4-04042025_050405.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,655 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 936 | $14.75 | $13,806.00 |
DisclosureSEC source: 0001415889-25-000924 · form4-01062025_070119.xml · nonDerivative · entry 3 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,788 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.75 inclusive. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 87,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000924 · form4-01062025_070119.xml · derivative · entry 4 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,000 Underlying: Ordinary Shares · 87,000 shares Expires 2035-01-02 F6 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 4,578 | $14.09 | $64,504.02 |
DisclosureSEC source: 0001415889-25-000924 · form4-01062025_070119.xml · nonDerivative · entry 2 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,724 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000924 · form4-01062025_070119.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,302 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 20:50 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 972 | $22.26 | $21,636.72 |
DisclosureSEC source: 0001415889-24-024769 · form4-10042024_041006.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,302 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.91 to $22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2024 Filed Jul 15, 2024 20:34 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 17,600 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001140361-24-033178 · form4.xml · derivative · entry 1 Milnes Alistair · CIK 0001901321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2034-07-12 F1 · derivative.exercise_date: The shares underlying the stock option vest one year from the date of grant, assuming continued service. Read SEC document |
| July 03, 2024 Filed Jul 8, 2024 22:55 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 967 | $19.64 | $18,991.88 |
DisclosureSEC source: 0001415889-24-019383 · form4-07082024_060701.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,274 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 955 | $23.81 | $22,738.55 |
DisclosureSEC source: 0001415889-24-010416 · form4-04052024_040434.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,241 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 23:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 2,643 | $17.50 | $46,252.50 |
DisclosureSEC source: 0001209191-24-000877 · doc4.xml · nonDerivative · entry 2 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,196 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $18.08 | $0.00 |
DisclosureSEC source: 0001209191-24-000877 · doc4.xml · derivative · entry 3 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Ordinary Shares · 77,000 shares Expires 2034-01-02 F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000877 · doc4.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,839 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 21:47 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 442 | $20.00 | $8,840.00 |
DisclosureSEC source: 0001209191-23-052251 · doc4.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,839 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.91 to $20.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:52 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 451 | $25.10 | $11,320.10 |
DisclosureSEC source: 0001209191-23-041573 · doc4.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,281 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.85 to $25.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:42 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001140361-23-030284 · form4.xml · derivative · entry 1 Milnes Alistair · CIK 0001901321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares underlying the stock option will vest in annual one-third (1/3) increments over a three (3) year period beginning on June 14, 2024, assuming continued service. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:42 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 447 | $21.11 | $9,436.17 |
DisclosureSEC source: 0001209191-23-023349 · doc4.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,732 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $21.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:19 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-23-002205 · doc4.xml · derivative · entry 3 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2033-01-03 F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:19 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,801 | $29.06 | $52,337.06 |
DisclosureSEC source: 0001209191-23-002205 · doc4.xml · nonDerivative · entry 2 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,179 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.545 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:19 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002205 · doc4.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,980 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2024 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:36 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,155 | $0.00 Strike: $20.12 | $0.00 |
DisclosureSEC source: 0001209191-22-021491 · doc4.xml · derivative · entry 2 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,845 Underlying: Ordinary Shares · 5,155 shares Expires 2031-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vested one-fourth (1/4) of the total number of shares underlying the option on January 4, 2022 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:36 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 5,155 | $20.12 | $103,718.60 |
DisclosureSEC source: 0001209191-22-021491 · doc4.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $60.87 | $0.00 |
DisclosureSEC source: 0001209191-22-001799 · doc4.xml · derivative · entry 2 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2023 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:15 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001799 · doc4.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2023 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.